Risk of subsequent primary leukaemias among 69,460 five-year survivors of childhood cancer diagnosed from 1940 to 2008 in Europe

Allodji, Rodrigue S; Hawkins, Mike M; Bright, Chloe J; Fidler-Benaoudia, Miranda M; Winter, David L; Alessi, Daniela; Fresneau, Brice; Journy, Neige; Morsellino, Vera; Bárdi, Edit; Bautz, Andrea; Byrne, Julianne; Feijen, Elizabeth Lieke Am; Teepen, Jop C; Vu-Bezin, Giao; Rubino, Carole; Garwicz, Stanislaw; Grabow, Desiree; Guha, Joyeeta

DOI: 10.1016/j.ejca.2019.05.013

License: Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Citation for published version (Harvard):
https://doi.org/10.1016/j.ejca.2019.05.013

Link to publication on Research at Birmingham portal
RISK OF SUBSEQUENT PRIMARY LEUKEMIAS AMONG 69,460 5-YEAR SURVIVORS OF CHILDHOOD CANCER IN EUROPE: A COHORT STUDY WITHIN PANCARESURFUP

Rodrigue S Allodji1,3,27, Mike M Hawkins1, Chloe J Bright1, David L Winter1, Daniela Alessi2, Brice Fresneau3,4, Miranda M Fidler-Benaoudia1,5, Vera Morsellino6, Edit Bárdi7,8, Andrea Bautz9, Julianne Byrne10, Elizabeth AM Feijen11,12, Giao Vu-Bezin3, Carole Rubino3, Stanislaw Garwicz13†, Desiree Grabow14, Thorgerdur Gudmundsdottir8,15, Joyeeta Guha1, Eva-Maria Hau1,6,17, Momcilo Jankovic48, Peter Kaatsch14, Melanie Kaiser14, Helena Linge13, Monica Muraca6, Neige Journy3, Damien Llanas3, Cristina Veres3, Hilde Øfstaas19, Ibrahim Diafio6, Imene Mansouri1, Cecile M Ronckers11,12, Roderick Skinner20, Jop C Teepen11,12, Monica Terenziani21, Finn Wenerg22, Thomas Wiebe13, Carlotta Sacerdot21, Zsuzsanna Jakab23, Riccardo Haupt2, Paivi Lähteenmäki24, Lorna Zadravec Zaletel25, Claudia E Kuehn16,17, Jeanette F Winther9,26, Leontien C Kremer11,12, Lars Hjort13, Nadia Haddy1,3, Florent de Vathaire3, Raoul C Reulen1

Affiliations:

1Centre for Childhood Cancer Survivor Studies, Institute of Applied Health Research, Robert Aitken Building, University of Birmingham, Birmingham, UK.
2Childhood Cancer Registry of Piedmont, Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and AOI Città della Salute e della Scienza di Torino, Italy.
3Cancer and Radiation Team, Center for Research in Epidemiology and Population Health, INSERM U1018, University Paris Saclay, Gustave Roussy, Villejuif, France.
4Department of Pediatric oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
5Department of Cancer Epidemiology and Prevention Research, Alberta Health Services, Calgary, Alberta, Canada.
6Epidemiology and Biostatistics Unit, Istituto Giannina Gaslini, Genova, Italy.
72nd Department of Pediatrics, Semmelweis University, Budapest, Hungary.
8Kepler Universitätssklinikum, Linz, Austria.
9Danish Cancer Society Research Center, Childhood Cancer research group, Copenhagen, Denmark.
10Boyne Research Institute, Drogheda, Ireland.
11Department of Pediatric Oncology, Emma Children’s Hospital/Academic Medical Center, Amsterdam, The Netherlands.
12Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
13Lund University, Skane University Hospital, Department of Clinical Sciences, Paediatrics, Lund, Sweden.
14German Childhood Cancer Registry (GCCR), Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center, Mainz, Germany.
15Children’s Hospital, Landspítali University Hospital, Reykjavik, Iceland.
16Swiss Childhood Cancer Registry, Institute of Social and Preventive Medicine, University of Bern, Switzerland.
17Department of Paediatrics, University Children's Hospital of Bern, University of Bern, Switzerland.
18Foundation MBBM, Hemato-Oncology Center, University of Milano-Bicocca, via Cadore 38, 20900 Monza (MB), Italy.
19Norwegian National Advisory Unit on solid tumors in children, Norway.
20Great North Children’s Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, and Northern Institute of Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
21Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
22Norwegian Cancer Registry and Dept. of Pediatric Medicine, Oslo University Hospital and Institute of Clinical Medicine, Faculty of medicine, University of Oslo, Norway.
23Hungarian Childhood Cancer Registry, 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary.
24Turku University and Turku University Hospital, Department of Pediatric and Adolescent Medicine, Turku, Finland.
25Institute of Oncology, Ljubljana, Slovenia.
26Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.
27Polytechnic School of Abomey-Calavi (EPAC), University of Abomey-Calavi, 01 P.O. Box 2009, Cotonou, Benin
28Deceased 27th November 2018 to whom this research is dedicated.
Background
Survivors of childhood cancers are at risk of developing subsequent primary leukemias (SPLs), but the long-term risks after 20 years following treatment are still unclear. We investigated the risk of SPLs in 5-year childhood cancer survivors using a large-scale pan-European (PanCareSurFup) cohort and evaluated variations in the risk by cancer and demographic factors.

Methods
This largest-ever assembled cohort comprises 69,460 5-year childhood cancer survivors from 12 European countries. Standardized incidence ratios (SIRs) and absolute excess risks (AERs) were calculated. Cumulative incidence was calculated accounting for competing risk of death.

Results
One hundred and fifteen survivors developed a SPL including 86 subsequent primary myeloid leukemias (SPML) and 17 subsequent primary lymphoid leukemias (SPLL); of these SPLs, 31 occurred beyond 20 years from first childhood cancer diagnosis. Compared with the general population, childhood cancer survivors had a 4-fold increased risk (SIR = 3.7; 95%CI: 3.1-4.5) of developing leukemia, and eight leukemias per 100,000 person-years (AER = 7.5; 95%CI: 6-9.2) occurred in excess of that expected. The risks remained significantly elevated beyond 20 years from first primary malignancy. Overall, the risk ratio for SPML (SIR = 5.8; 95%CI: 4.6-7.1) was higher than that for all other SPLs combined.

Conclusions
We demonstrate that beyond 20 years after childhood cancer diagnosis survivors experience an increased risk for SPLs compared to that expected from the general population. Our findings show that awareness for symptoms potentially related to subsequent leukemias among long-term survivors of childhood cancer needs to continue well into middle age.